$BMRN
BIOMARIN PHARMACEUTICAL INC

2013 Q2 Form 10-Q Financial Statement

#000119312513306978 Filed on July 29, 2013

View on sec.gov

Income Statement

Concept 2013 Q2 2012 Q2
Revenue $136.8M $124.0M
YoY Change 10.31% 12.1%
Cost Of Revenue $22.57M $23.57M
YoY Change -4.27% 22.38%
Gross Profit $114.2M $100.4M
YoY Change 13.74% 9.93%
Gross Profit Margin 83.5% 80.99%
Selling, General & Admin $50.66M $51.54M
YoY Change -1.71% 25.66%
% of Gross Profit 44.34% 51.31%
Research & Development $85.66M $77.81M
YoY Change 10.09% 47.07%
% of Gross Profit 74.98% 77.47%
Depreciation & Amortization $9.400M $8.400M
YoY Change 11.9% 13.51%
% of Gross Profit 8.23% 8.36%
Operating Expenses $136.3M $129.4M
YoY Change 5.39% 37.72%
Operating Profit -$20.05M -$30.95M
YoY Change -35.22% -4130.47%
Interest Expense $603.0K $1.925M
YoY Change -68.68% -12.54%
% of Operating Profit
Other Income/Expense, Net -$100.0K -$200.0K
YoY Change -50.0% -300.0%
Pretax Income -$20.29M -$32.42M
YoY Change -37.41% 2663.6%
Income Tax $1.242M -$411.0K
% Of Pretax Income
Net Earnings -$21.53M -$32.01M
YoY Change -32.72% 530.41%
Net Earnings / Revenue -15.74% -25.81%
Basic Earnings Per Share -$0.15 -$0.27
Diluted Earnings Per Share -$0.16 -$0.27
COMMON SHARES
Basic Shares Outstanding 139.4M shares 117.9M shares
Diluted Shares Outstanding 139.6M shares 117.9M shares

Balance Sheet

Concept 2013 Q2 2012 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $400.6M $402.6M
YoY Change -0.5% 55.5%
Cash & Equivalents $175.4M $177.8M
Short-Term Investments $225.1M $224.8M
Other Short-Term Assets $33.53M $58.07M
YoY Change -42.27% 83.78%
Inventory $142.3M $120.1M
Prepaid Expenses $14.87M
Receivables $115.1M $100.8M
Other Receivables $0.00 $9.700M
Total Short-Term Assets $720.9M $681.5M
YoY Change 5.78% 32.57%
LONG-TERM ASSETS
Property, Plant & Equipment $282.0M $267.4M
YoY Change 5.47% 23.5%
Goodwill $54.98M $51.54M
YoY Change 6.66%
Intangibles $168.4M $168.3M
YoY Change 0.1%
Long-Term Investments $124.9M $123.2M
YoY Change 1.38% -20.16%
Other Assets $14.88M $20.06M
YoY Change -25.81% -91.67%
Total Long-Term Assets $880.6M $851.0M
YoY Change 3.48% 11.05%
TOTAL ASSETS
Total Short-Term Assets $720.9M $681.5M
Total Long-Term Assets $880.6M $851.0M
Total Assets $1.602B $1.533B
YoY Change 4.5% 19.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $16.26M $12.50M
YoY Change 30.07% 71.25%
Accrued Expenses $52.10M $32.45M
YoY Change 60.55% -44.53%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $23.40M
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $142.2M $120.0M
YoY Change 18.54% 46.34%
LONG-TERM LIABILITIES
Long-Term Debt $109.8M $324.9M
YoY Change -66.2% -13.93%
Other Long-Term Liabilities $30.76M $87.24M
YoY Change -64.75% 67.77%
Total Long-Term Liabilities $30.76M $87.24M
YoY Change -64.75% -79.69%
TOTAL LIABILITIES
Total Short-Term Liabilities $142.2M $120.0M
Total Long-Term Liabilities $30.76M $87.24M
Total Liabilities $343.3M $532.1M
YoY Change -35.49% -2.92%
SHAREHOLDERS EQUITY
Retained Earnings -$600.8M -$481.1M
YoY Change 24.88%
Common Stock $1.864B $1.483B
YoY Change 25.66%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.258B $1.000B
YoY Change
Total Liabilities & Shareholders Equity $1.602B $1.533B
YoY Change 4.5% 19.69%

Cashflow Statement

Concept 2013 Q2 2012 Q2
OPERATING ACTIVITIES
Net Income -$21.53M -$32.01M
YoY Change -32.72% 530.41%
Depreciation, Depletion And Amortization $9.400M $8.400M
YoY Change 11.9% 13.51%
Cash From Operating Activities -$6.800M -$1.400M
YoY Change 385.71% -110.29%
INVESTING ACTIVITIES
Capital Expenditures -$10.40M -$9.500M
YoY Change 9.47% 375.0%
Acquisitions
YoY Change
Other Investing Activities $22.70M -$142.9M
YoY Change -115.89% -5596.15%
Cash From Investing Activities $12.20M -$152.3M
YoY Change -108.01% -21857.14%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $235.5M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 15.60M 249.0M
YoY Change -93.73% 3051.9%
NET CHANGE
Cash From Operating Activities -6.800M -1.400M
Cash From Investing Activities 12.20M -152.3M
Cash From Financing Activities 15.60M 249.0M
Net Change In Cash 21.00M 95.30M
YoY Change -77.96% 329.28%
FREE CASH FLOW
Cash From Operating Activities -$6.800M -$1.400M
Capital Expenditures -$10.40M -$9.500M
Free Cash Flow $3.600M $8.100M
YoY Change -55.56% -48.08%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
140105591 shares
CY2012Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
177757000
CY2013Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
140050009 shares
CY2013Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2013Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
140050009 shares
CY2013Q2 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
1995000
CY2013Q2 us-gaap Convertible Debt
ConvertibleDebt
109822000
CY2013Q2 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
3957000
CY2013Q2 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
62736000
CY2013Q2 us-gaap Asset Retirement Obligation
AssetRetirementObligation
4000000
CY2013Q2 us-gaap Liabilities Current
LiabilitiesCurrent
142241000
CY2013Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2441000
CY2013Q2 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
109822000
CY2013Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
18229000
CY2013Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
167268000
CY2013Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1363000
CY2013Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
16260000
CY2013Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
30756000
CY2013Q2 us-gaap Stockholders Equity
StockholdersEquity
1258258000
CY2013Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1863961000
CY2013Q2 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
4496000
CY2013Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
142241000
CY2013Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-600791000
CY2013Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
52098000
CY2013Q2 us-gaap Deferred Compensation Cash Based Arrangements Liability Current
DeferredCompensationCashBasedArrangementsLiabilityCurrent
1760000
CY2013Q2 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
0
CY2013Q2 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
10712000
CY2013Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
175445000
CY2013Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
376000
CY2013Q2 us-gaap Accrued Vacation Current
AccruedVacationCurrent
10409000
CY2013Q2 us-gaap Liabilities
Liabilities
343262000
CY2013Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
24238000
CY2013Q2 us-gaap Common Stock Value
CommonStockValue
140000
CY2013Q2 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
323975000
CY2013Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1601520000
CY2013Q2 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
37182000
CY2013Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
14883000
CY2013Q2 us-gaap Land
Land
11608000
CY2013Q2 us-gaap Goodwill
Goodwill
54975000
CY2013Q2 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
346262000
CY2013Q2 us-gaap Common Stock Issued Employee Stock Trust
CommonStockIssuedEmployeeStockTrust
7493000
CY2013Q2 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
65702000
CY2013Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
168434000
CY2013Q2 us-gaap Financing Receivable Recorded Investment Past Due
FinancingReceivableRecordedInvestmentPastDue
4125000
CY2013Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
115063000
CY2013Q2 us-gaap Inventory Net
InventoryNet
142296000
CY2013Q2 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
74430000
CY2013Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
449270000
CY2013Q2 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
29474000
CY2013Q2 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
84258000
CY2013Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
55004000
CY2013Q2 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
1001000
CY2013Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
282002000
CY2013Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
72464000
CY2013Q2 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
235400000
CY2013Q2 us-gaap Assets
Assets
1601520000
CY2013Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
533300000
CY2013Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
175445000
CY2013Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
14828000
CY2013Q2 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
12053000
CY2013Q2 us-gaap Short Term Investments
ShortTermInvestments
225116000
CY2013Q2 us-gaap Buildings And Improvements Gross
BuildingsAndImprovementsGross
146999000
CY2013Q2 us-gaap Other Assets Current
OtherAssetsCurrent
33526000
CY2013Q2 us-gaap Construction In Progress Gross
ConstructionInProgressGross
68211000
CY2013Q2 us-gaap Available For Sale Securities
AvailableForSaleSecurities
349021000
CY2013Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
118242000
CY2013Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
225116000
CY2013Q2 us-gaap Long Term Investments
LongTermInvestments
123905000
CY2013Q2 us-gaap Available For Sale Securities Debt Maturities Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAmortizedCost
349021000
CY2012Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
6179000
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
23993000
CY2012Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
26674000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
1015763000
CY2012Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1561890000
CY2013Q2 us-gaap Assets Current
AssetsCurrent
720920000
CY2013Q2 bmrn Computer Hardware And Software
ComputerHardwareAndSoftware
60439000
CY2013Q2 bmrn Other Liabilities Noncurrent Fair Value Disclosure
OtherLiabilitiesNoncurrentFairValueDisclosure
39479000
CY2013Q2 bmrn Available For Sale Securities Debt Maturities After One Through Two Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
123905000
CY2013Q2 bmrn Contingent And Deferred Acquisition Payments
ContingentAndDeferredAcquisitionPayments
23261000
CY2013Q2 bmrn Other Liabilities Current Fair Value Disclosure
OtherLiabilitiesCurrentFairValueDisclosure
23257000
CY2013Q2 bmrn Other Assets Current Fair Value Disclosure
OtherAssetsCurrentFairValueDisclosure
3563000
CY2013Q2 bmrn Gross Intangible Assets
GrossIntangibleAssets
192672000
CY2013Q2 bmrn Other Assets Noncurrent Fair Value Disclosure
OtherAssetsNoncurrentFairValueDisclosure
5271000
CY2013Q2 bmrn Business Combination Contingent Consideration At Fair Value Current
BusinessCombinationContingentConsiderationAtFairValueCurrent
20962000
CY2013Q2 bmrn Available For Sale Securities Gross Unrealized Gain Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
3259000
CY2013Q2 bmrn Available For Sale Securities Gross Unrealized Loss Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
500000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
46272000
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
125809162 shares
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
125809162 shares
CY2012Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
3915000
CY2012Q4 us-gaap Convertible Debt
ConvertibleDebt
348224000
CY2012Q4 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
2072000
CY2012Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
62613000
CY2012Q4 us-gaap Asset Retirement Obligation
AssetRetirementObligation
3900000
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
170433000
CY2012Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-202000
CY2012Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
324859000
CY2012Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
27530000
CY2012Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
149122000
CY2012Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
4991000
CY2012Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
147068000
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-539448000
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
43156000
CY2012Q4 us-gaap Deferred Compensation Cash Based Arrangements Liability Current
DeferredCompensationCashBasedArrangementsLiabilityCurrent
6440000
CY2012Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
23365000
CY2012Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
9625000
CY2012Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
348000
CY2012Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
8403000
CY2012Q4 us-gaap Liabilities
Liabilities
585880000
CY2012Q4 bmrn Other Liabilities Noncurrent Fair Value Disclosure
OtherLiabilitiesNoncurrentFairValueDisclosure
42646000
CY2012Q4 bmrn Available For Sale Securities Debt Maturities After One Through Two Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
115993000
CY2012Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
18951000
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
126000
CY2012Q4 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
811798000
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1601643000
CY2012Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
33296000
CY2012Q4 us-gaap Asset Retirement Obligation Current
AssetRetirementObligationCurrent
1685000
CY2012Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
16611000
CY2012Q4 us-gaap Land
Land
11608000
CY2012Q4 us-gaap Goodwill
Goodwill
51543000
CY2012Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
386010000
CY2012Q4 us-gaap Common Stock Issued Employee Stock Trust
CommonStockIssuedEmployeeStockTrust
6603000
CY2012Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
65918000
CY2012Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
162980000
CY2012Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
109066000
CY2012Q4 us-gaap Inventory Net
InventoryNet
128695000
CY2012Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
63689000
CY2012Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
433595000
CY2012Q4 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
29454000
CY2012Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
79915000
CY2012Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
45309000
CY2012Q4 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
1080000
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
284473000
CY2012Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
71443000
CY2012Q4 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
225501000
CY2012Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
180527000
CY2012Q4 us-gaap Assets
Assets
1601643000
CY2012Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
578440000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
180527000
CY2012Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
11943000
CY2012Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
11143000
CY2012Q4 us-gaap Short Term Investments
ShortTermInvestments
270211000
CY2012Q4 us-gaap Buildings And Improvements Gross
BuildingsAndImprovementsGross
144700000
CY2012Q4 us-gaap Other Assets Current
OtherAssetsCurrent
25509000
CY2012Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
64300000
CY2012Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
386204000
CY2012Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
118242000
CY2012Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
270211000
CY2012Q4 us-gaap Long Term Investments
LongTermInvestments
115993000
CY2012Q4 us-gaap Available For Sale Securities Debt Maturities Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAmortizedCost
386204000
CY2012Q4 us-gaap Assets Current
AssetsCurrent
743462000
CY2012Q4 bmrn Computer Hardware And Software
ComputerHardwareAndSoftware
56011000
CY2012Q4 bmrn Business Combination Contingent Consideration At Fair Value Current
BusinessCombinationContingentConsiderationAtFairValueCurrent
10764000
CY2012Q4 bmrn Available For Sale Securities Gross Unrealized Gain Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
473000
CY2012Q4 bmrn Contingent And Deferred Acquisition Payments
ContingentAndDeferredAcquisitionPayments
30618000
CY2012Q4 bmrn Other Liabilities Current Fair Value Disclosure
OtherLiabilitiesCurrentFairValueDisclosure
19967000
CY2012Q4 bmrn Other Assets Current Fair Value Disclosure
OtherAssetsCurrentFairValueDisclosure
5842000
CY2012Q4 bmrn Gross Intangible Assets
GrossIntangibleAssets
181931000
CY2012Q4 bmrn Other Assets Noncurrent Fair Value Disclosure
OtherAssetsNoncurrentFairValueDisclosure
5867000
CY2012Q4 bmrn Available For Sale Securities Gross Unrealized Loss Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
279000
dei Trading Symbol
TradingSymbol
BMRN
dei Entity Registrant Name
EntityRegistrantName
BIOMARIN PHARMACEUTICAL INC
dei Amendment Flag
AmendmentFlag
false
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2013-06-30
dei Entity Central Index Key
EntityCentralIndexKey
0001048477
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
us-gaap Basis Of Accounting
BasisOfAccounting
<div> <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:Times New Roman" size="2"><b>(2) BASIS OF PRESENTATION</b></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"> <font style="font-family:Times New Roman" size="2">The accompanying Condensed Consolidated Financial Statements have been prepared pursuant to the rules and regulations of the SEC for Quarterly Reports on Form 10-Q and do not include all of the information and note disclosures required by U.S. generally accepted accounting principles (U.S. GAAP) for complete financial statements. The Condensed Consolidated Financial Statements should therefore be read in conjunction with the Consolidated Financial Statements and Notes thereto for the fiscal year ended December&#xA0;31, 2012 included in the Company&#x2019;s Annual Report on Form 10-K.</font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"> <font style="font-family:Times New Roman" size="2">The accompanying Condensed Consolidated Financial Statements have been prepared in accordance with U.S. GAAP, which requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying disclosures. Although these estimates are based on management&#x2019;s best knowledge of current events and actions that the Company may undertake in the future, actual results may be different from those estimates. The Condensed Consolidated Financial Statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair presentation of results for these interim periods. The results of operations for the three and six months ended June&#xA0;30, 2013 are not necessarily indicative of the results that may be expected for the fiscal year ending December&#xA0;31, 2013.</font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"> <font style="font-family:Times New Roman" size="2">The Company has evaluated events and transactions subsequent to the balance sheet date. Based on this evaluation, the Company is not aware of any events or transactions that occurred subsequent to the balance sheet date but prior to filing this Quarterly Report on Form 10-Q that would require recognition or disclosure in the Condensed Consolidated Financial Statements.</font></p> </div>
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.46
us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:Times New Roman" size="2"><b>(1) NATURE OF OPERATIONS AND BUSINESS RISKS</b></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"> <font style="font-family:Times New Roman" size="2">BioMarin Pharmaceutical Inc. (the Company or BioMarin), a Delaware corporation, develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. BioMarin selects product candidates for diseases and conditions that represent a significant unmet medical need, have well-understood biology and provide an opportunity to be first-to-market or offer a significant benefit over existing products. The Company&#x2019;s product portfolio is comprised of four approved products and multiple investigational product candidates. The Company&#x2019;s approved products are Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Firdapse (amifampridine phosphate) and Aldurazyme (laronidase).</font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"> <font style="font-family:Times New Roman" size="2">Through June&#xA0;30, 2013, the Company had accumulated losses of approximately $600.8 million. Management believes that the Company&#x2019;s cash, cash equivalents and short-term and long-term investments at June&#xA0;30, 2013 will be sufficient to meet the Company&#x2019;s obligations for at least the next twelve months based on management&#x2019;s current business plans. If the Company elects to increase its spending on development programs significantly above current long-term plans or enters into potential licenses and other acquisitions of complementary technologies, products or companies, the Company may need additional capital. The Company expects to continue to finance future cash needs that exceed its operating activities primarily through its current cash, cash equivalents, short-term and long-term investments, and to the extent necessary, through proceeds from equity or debt financings, loans and collaborative agreements with corporate partners.</font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"> <font style="font-family:Times New Roman" size="2">The Company is subject to a number of risks, including: the financial performance of Naglazyme, Kuvan, Firdapse and Aldurazyme; the potential need for additional financings; its ability to successfully commercialize its product candidates, if approved; the uncertainty of the Company&#x2019;s research and development efforts resulting in future successful commercial products; obtaining regulatory approval for new products; significant competition from larger organizations; reliance on the proprietary technology of others; dependence on key personnel; uncertain patent protection; dependence on corporate partners and collaborators; and possible restrictions on reimbursement from governmental agencies and healthcare organizations, as well as other changes in the health care industry.</font></p> </div>
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
133716000 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
2.2 shares
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.46
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
30.45
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-38846000
us-gaap Description Of New Accounting Pronouncements Not Yet Adopted
DescriptionOfNewAccountingPronouncementsNotYetAdopted
<div> <p style="margin-top:0px;margin-bottom:0px"><font style="font-family:Times New Roman" size="2"><b>(4) RECENT ACCOUNTING PRONOUNCEMENTS</b></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"> <font style="font-family:Times New Roman" size="2">Except for Financial Accounting Standards Board (FASB) Accounting Standards Update 2013-02 (ASU 2013-02), <i>Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income,</i> there have been no new accounting pronouncements or changes to accounting pronouncements during the period ended June&#xA0;30, 2013, as compared to the recent accounting pronouncements described in the Company&#x2019;s Annual Report on Form 10-K for the year-ended December&#xA0;31, 2012, that are of significance or potential significance to the Company. ASU 2013-02 requires an entity to present either on the face of the financial statements where income is presented or in the notes to the financial statements, significant amounts reclassified out of accumulated other comprehensive income by the respective line items of net income. See Note 18 to the accompanying Condensed Consolidated Financial Statements for the expanded disclosures required by ASU 2013-02.</font></p> </div>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20929000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
133716000 shares
us-gaap Employee Stock Ownership Plan Esop Gain Loss On Transactions In Deferred Shares
EmployeeStockOwnershipPlanESOPGainLossOnTransactionsInDeferredShares
0
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-564000
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
10420000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
22238000
us-gaap Income Taxes Paid
IncomeTaxesPaid
11388000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1368000
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
259744000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-61343000
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
105000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
9875000
us-gaap Excess Tax Benefit From Share Based Compensation Operating Activities
ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
453000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
6359000
us-gaap Payments To Acquire Interest In Joint Venture
PaymentsToAcquireInterestInJointVenture
485000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-61343000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
118181000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
1397000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-64812000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5997000
us-gaap Maturities Of Subordinated Debt
MaturitiesOfSubordinatedDebt
98000
us-gaap Derivative Instruments Gain Loss Recognized In Other Comprehensive Income Effective Portion Net
DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet
1200000
us-gaap Interest Paid Net
InterestPaidNet
3033000
us-gaap Revenues
Revenues
264738000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-58700000
us-gaap Contracts Revenue
ContractsRevenue
1024000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
385000
us-gaap Operating Income Loss
OperatingIncomeLoss
-52973000
us-gaap Royalty Revenue
RoyaltyRevenue
3970000
us-gaap Other Comprehensive Income Loss Before Reclassifications Net Of Tax
OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
3197000
us-gaap Net Income Loss
NetIncomeLoss
-61343000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-2829000
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
286000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
13601000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
2643000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
238304000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
984000
us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
554000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
155099000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-9722000
us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
3432000
us-gaap Costs And Expenses
CostsAndExpenses
317711000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
29444000
us-gaap Share Based Compensation
ShareBasedCompensation
25848000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
24505000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-5082000
us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
10420000
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
2315000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
101706000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3469000
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax
800000
us-gaap Interest Expense
InterestExpense
2328000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
939000
us-gaap Cost Of Revenue
CostOfRevenue
43067000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
2017000
us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
453000
us-gaap Depreciation
Depreciation
18100000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
25494000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
4320000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
169404000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
39795000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-7695000
bmrn Depreciation Expense Capitalized Into Inventory
DepreciationExpenseCapitalizedIntoInventory
5391000
bmrn Intangible Asset Amortization And Contingent Consideration
IntangibleAssetAmortizationAndContingentConsideration
3534000
bmrn Stock Based Compensation Capitalized To Inventory
StockBasedCompensationCapitalizedToInventory
2400000
bmrn Percentage Of Product Revenue Exceeding Consolidated Net Product Revenue
PercentageOfProductRevenueExceedingConsolidatedNetProductRevenue
0.10 pure
bmrn Stockbased Compensation Capitalized
StockbasedCompensationCapitalized
2390000
bmrn Contingent Payments Upon Achievement Of Certain Regulatory And Licensing Milestones
ContingentPaymentsUponAchievementOfCertainRegulatoryAndLicensingMilestones
437600000
bmrn Supplemental Accounts Payable And Accrued Liabilities
SupplementalAccountsPayableAndAccruedLiabilities
7125000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
116496000 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8591000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
35520000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
116496000 shares
us-gaap Employee Stock Ownership Plan Esop Gain Loss On Transactions In Deferred Shares
EmployeeStockOwnershipPlanESOPGainLossOnTransactionsInDeferredShares
0
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-632000
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
15663000
us-gaap Income Taxes Paid
IncomeTaxesPaid
4914000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1041000
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
239230000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-55978000
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-140000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0
us-gaap Excess Tax Benefit From Share Based Compensation Operating Activities
ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
84000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
14176000
us-gaap Payments To Acquire Interest In Joint Venture
PaymentsToAcquireInterestInJointVenture
1258000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-55978000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
212471000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
2340000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-56423000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-4089000
us-gaap Maturities Of Subordinated Debt
MaturitiesOfSubordinatedDebt
0
us-gaap Interest Paid Net
InterestPaidNet
3367000
us-gaap Revenues
Revenues
240668000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-56215000
us-gaap Contracts Revenue
ContractsRevenue
519000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
6235000
us-gaap Operating Income Loss
OperatingIncomeLoss
-52820000
us-gaap Royalty Revenue
RoyaltyRevenue
919000
us-gaap Net Income Loss
NetIncomeLoss
-55978000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1738000
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
393000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-9993000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
0
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-3942000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
107047000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
143000
us-gaap Costs And Expenses
CostsAndExpenses
293488000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
262421000
us-gaap Share Based Compensation
ShareBasedCompensation
23424000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
21771000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
131485000
us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
0
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
0
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
96787000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-445000
us-gaap Interest Expense
InterestExpense
3872000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
235444000
us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
6707000
us-gaap Cost Of Revenue
CostOfRevenue
40679000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
4235000
us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
84000
us-gaap Depreciation
Depreciation
16800000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
23765000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-122345000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
151646000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
27286000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1432000
bmrn Depreciation Expense Capitalized Into Inventory
DepreciationExpenseCapitalizedIntoInventory
2275000
bmrn Intangible Asset Amortization And Contingent Consideration
IntangibleAssetAmortizationAndContingentConsideration
4376000
bmrn Stock Based Compensation Capitalized To Inventory
StockBasedCompensationCapitalizedToInventory
1900000
bmrn Stockbased Compensation Capitalized
StockbasedCompensationCapitalized
1861000
bmrn Supplemental Accounts Payable And Accrued Liabilities
SupplementalAccountsPayableAndAccruedLiabilities
1170000
CY2012 us-gaap Derivative Instruments Gain Loss Recognized In Other Comprehensive Income Effective Portion Net
DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet
200000
CY2012 bmrn Number Of Customers Accounted For Largest Balance In Account Receivable
NumberOfCustomersAccountedForLargestBalanceInAccountReceivable
2 Customer
CY2012Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.27
CY2012Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.27
CY2012Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
117912000 shares
CY2012Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2012Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
35526000 shares
CY2012Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
117912000 shares
CY2012Q2 us-gaap Employee Stock Ownership Plan Esop Gain Loss On Transactions In Deferred Shares
EmployeeStockOwnershipPlanESOPGainLossOnTransactionsInDeferredShares
0
CY2012Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
102000
CY2012Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
536000
CY2012Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
122991000
CY2012Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-32006000
CY2012Q2 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-176000
CY2012Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-32006000
CY2012Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-32417000
CY2012Q2 us-gaap Revenues
Revenues
124019000
CY2012Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-29868000
CY2012Q2 us-gaap Contracts Revenue
ContractsRevenue
423000
CY2012Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-30954000
CY2012Q2 us-gaap Royalty Revenue
RoyaltyRevenue
605000
CY2012Q2 us-gaap Net Income Loss
NetIncomeLoss
-32006000
CY2012Q2 us-gaap Costs And Expenses
CostsAndExpenses
154973000
CY2012Q2 us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
0
CY2012Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
51539000
CY2012Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-411000
CY2012Q2 us-gaap Interest Expense
InterestExpense
1925000
CY2012Q2 us-gaap Cost Of Revenue
CostOfRevenue
23574000
CY2012Q2 us-gaap Depreciation
Depreciation
8400000
CY2012Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12637000
CY2012Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
77812000
CY2012Q2 bmrn Depreciation Expense Capitalized Into Inventory
DepreciationExpenseCapitalizedIntoInventory
1200000
CY2012Q2 bmrn Intangible Asset Amortization And Contingent Consideration
IntangibleAssetAmortizationAndContingentConsideration
2048000
CY2013Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.15
CY2013Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
CY2013Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
139596000 shares
CY2013Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
196000 shares
CY2013Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20777000 shares
CY2013Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
139400000 shares
CY2013Q2 us-gaap Employee Stock Ownership Plan Esop Gain Loss On Transactions In Deferred Shares
EmployeeStockOwnershipPlanESOPGainLossOnTransactionsInDeferredShares
-1277000
CY2013Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-163000
CY2013Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
650000
CY2013Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
132400000
CY2013Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-21533000
CY2013Q2 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-123000
CY2013Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-22810000
CY2013Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-20291000
CY2013Q2 us-gaap Revenues
Revenues
136810000
CY2013Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-20247000
CY2013Q2 us-gaap Contracts Revenue
ContractsRevenue
889000
CY2013Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-20052000
CY2013Q2 us-gaap Royalty Revenue
RoyaltyRevenue
3521000
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-21533000
CY2013Q2 us-gaap Costs And Expenses
CostsAndExpenses
156862000
CY2013Q2 us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
0
CY2013Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
50656000
CY2013Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1242000
CY2013Q2 us-gaap Interest Expense
InterestExpense
603000
CY2013Q2 us-gaap Cost Of Revenue
CostOfRevenue
22567000
CY2013Q2 us-gaap Depreciation
Depreciation
9400000
CY2013Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13929000
CY2013Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
85661000
CY2013Q2 bmrn Depreciation Expense Capitalized Into Inventory
DepreciationExpenseCapitalizedIntoInventory
2800000
CY2013Q2 bmrn Intangible Asset Amortization And Contingent Consideration
IntangibleAssetAmortizationAndContingentConsideration
-2022000

Files In Submission

Name View Source Status
0001193125-13-306978-index-headers.html Edgar Link pending
0001193125-13-306978-index.html Edgar Link pending
0001193125-13-306978.txt Edgar Link pending
0001193125-13-306978-xbrl.zip Edgar Link pending
bmrn-20130630.xml Edgar Link completed
bmrn-20130630.xsd Edgar Link pending
bmrn-20130630_cal.xml Edgar Link unprocessable
bmrn-20130630_def.xml Edgar Link unprocessable
bmrn-20130630_lab.xml Edgar Link unprocessable
bmrn-20130630_pre.xml Edgar Link unprocessable
d552366d10q.htm Edgar Link pending
d552366dex311.htm Edgar Link pending
d552366dex312.htm Edgar Link pending
d552366dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
R1.htm Edgar Link pending
R1.xml Edgar Link unprocessable
R10.htm Edgar Link pending
R10.xml Edgar Link unprocessable
R11.htm Edgar Link pending
R11.xml Edgar Link unprocessable
R12.htm Edgar Link pending
R12.xml Edgar Link unprocessable
R13.htm Edgar Link pending
R13.xml Edgar Link unprocessable
R14.htm Edgar Link pending
R14.xml Edgar Link unprocessable
R15.htm Edgar Link pending
R15.xml Edgar Link unprocessable
R16.htm Edgar Link pending
R16.xml Edgar Link unprocessable
R17.htm Edgar Link pending
R17.xml Edgar Link unprocessable
R18.htm Edgar Link pending
R18.xml Edgar Link unprocessable
R19.htm Edgar Link pending
R19.xml Edgar Link unprocessable
R2.htm Edgar Link pending
R2.xml Edgar Link unprocessable
R20.htm Edgar Link pending
R20.xml Edgar Link unprocessable
R21.htm Edgar Link pending
R21.xml Edgar Link unprocessable
R22.htm Edgar Link pending
R22.xml Edgar Link unprocessable
R23.htm Edgar Link pending
R23.xml Edgar Link unprocessable
R24.htm Edgar Link pending
R24.xml Edgar Link unprocessable
R25.htm Edgar Link pending
R25.xml Edgar Link unprocessable
R26.htm Edgar Link pending
R26.xml Edgar Link unprocessable
R27.htm Edgar Link pending
R27.xml Edgar Link unprocessable
R28.htm Edgar Link pending
R28.xml Edgar Link unprocessable
R29.htm Edgar Link pending
R29.xml Edgar Link unprocessable
R3.htm Edgar Link pending
R3.xml Edgar Link unprocessable
R30.htm Edgar Link pending
R30.xml Edgar Link unprocessable
R31.htm Edgar Link pending
R31.xml Edgar Link unprocessable
R32.htm Edgar Link pending
R32.xml Edgar Link unprocessable
R33.htm Edgar Link pending
R33.xml Edgar Link unprocessable
R34.htm Edgar Link pending
R34.xml Edgar Link unprocessable
R35.htm Edgar Link pending
R35.xml Edgar Link unprocessable
R36.htm Edgar Link pending
R36.xml Edgar Link unprocessable
R37.htm Edgar Link pending
R37.xml Edgar Link unprocessable
R38.htm Edgar Link pending
R38.xml Edgar Link unprocessable
R39.htm Edgar Link pending
R39.xml Edgar Link unprocessable
R4.htm Edgar Link pending
R4.xml Edgar Link unprocessable
R40.htm Edgar Link pending
R40.xml Edgar Link unprocessable
R41.htm Edgar Link pending
R41.xml Edgar Link unprocessable
R42.htm Edgar Link pending
R42.xml Edgar Link unprocessable
R43.htm Edgar Link pending
R43.xml Edgar Link unprocessable
R44.htm Edgar Link pending
R44.xml Edgar Link unprocessable
R45.htm Edgar Link pending
R45.xml Edgar Link unprocessable
R46.htm Edgar Link pending
R46.xml Edgar Link unprocessable
R47.htm Edgar Link pending
R47.xml Edgar Link unprocessable
R48.htm Edgar Link pending
R48.xml Edgar Link unprocessable
R49.htm Edgar Link pending
R49.xml Edgar Link unprocessable
R5.htm Edgar Link pending
R5.xml Edgar Link unprocessable
R50.htm Edgar Link pending
R50.xml Edgar Link unprocessable
R51.htm Edgar Link pending
R51.xml Edgar Link unprocessable
R52.htm Edgar Link pending
R52.xml Edgar Link unprocessable
R53.htm Edgar Link pending
R53.xml Edgar Link unprocessable
R54.htm Edgar Link pending
R54.xml Edgar Link unprocessable
R55.htm Edgar Link pending
R55.xml Edgar Link unprocessable
R56.htm Edgar Link pending
R56.xml Edgar Link unprocessable
R57.htm Edgar Link pending
R57.xml Edgar Link unprocessable
R58.htm Edgar Link pending
R58.xml Edgar Link unprocessable
R59.htm Edgar Link pending
R59.xml Edgar Link unprocessable
R6.htm Edgar Link pending
R6.xml Edgar Link unprocessable
R60.htm Edgar Link pending
R60.xml Edgar Link unprocessable
R61.htm Edgar Link pending
R61.xml Edgar Link unprocessable
R62.htm Edgar Link pending
R62.xml Edgar Link unprocessable
R63.htm Edgar Link pending
R63.xml Edgar Link unprocessable
R64.htm Edgar Link pending
R64.xml Edgar Link unprocessable
R65.htm Edgar Link pending
R65.xml Edgar Link unprocessable
R66.htm Edgar Link pending
R66.xml Edgar Link unprocessable
R67.htm Edgar Link pending
R67.xml Edgar Link unprocessable
R68.htm Edgar Link pending
R68.xml Edgar Link unprocessable
R69.htm Edgar Link pending
R69.xml Edgar Link unprocessable
R7.htm Edgar Link pending
R7.xml Edgar Link unprocessable
R70.htm Edgar Link pending
R70.xml Edgar Link unprocessable
R71.htm Edgar Link pending
R71.xml Edgar Link unprocessable
R72.htm Edgar Link pending
R72.xml Edgar Link unprocessable
R8.htm Edgar Link pending
R8.xml Edgar Link unprocessable
R9.htm Edgar Link pending
R9.xml Edgar Link unprocessable
report.css Edgar Link pending
Show.js Edgar Link pending